Acer Therapeutics Inc

Acer Therapeutics — Opexa Therapeutics — Q2 2013 Earnings Presentation

11 slides from Acer Therapeutics's earnings presentation, Aug 14, 2013

  1. Slide 1: Second Quarter 2013 Earnings Update Call

    Opexa Therapeutics, Inc. Second Quarter 2013 Earnings Update Call 14 August 2013 NASDAQ: OPXA Precision Immunotherapy TM

  2. Slide 2: Forward-Looking Statements

    2 Forward-Looking Statements This earnings presentation contains forward-looking statements which are made pursuant to the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Statements contained in this

  3. Slide 3: Investment Thesis

    3 Investment Thesis • T-cell platform company • Esteemed Scientific Advisory Board • Precision ImmunotherapyTM potentially optimizes benefit-risk profile • Targeting an unmet medical need in a potentially substantial market • Option Agreement with Merck Serono, a strong commercial partner • Replacem

  4. Slide 4: Pipeline and Potential Areas of Investigation

    4 Pipeline and Potential Areas of Investigation Stage of Development * Rights granted to Merck Serono under option and license agreement (Feb. 5, 2013)

  5. Slide 5: Tcelna in Secondary Progressive Multiple Sclerosis

    5 Tcelna® in Secondary Progressive Multiple Sclerosis • Patients initially experience a relapsingremitting course then transition to SPMS • SPMS patients experience worsening QOL / disability with or without relapses • Over 450,000 patients in North America and over 2 million worldwide have MS • App

  6. Slide 6: Merck Serono Agreement for MS indication

    6 Merck Serono Agreement for MS indication • February 2013 option and license agreement with Merck Serono – Up to $220 million in additional payments • Option exercise $25 million for starting Phase III/ or $15 million if another Phase II • $35 million FDA filing, approval and commercialized in US •

  7. Slide 7: Financials (unaudited)

    7 Financials (unaudited) Income Statement Q2 2013 Q2 2012 Option Revenue $348,837 - Research & Development $2,223,030 $1,558,208 General & Administrative $750,605 $529,566 Earnings Per Share $ (0.37) $ (0.38) Balance Sheet Details June 30, 2013 Dec 31, 2012 Cash and Cash Equivalents $5,028,280(1) $5

  8. Slide 8: Tcelna Development Program

    8 Tcelna Development Program Broad Spectrum of MS patients treated * Expected upon completion of ongoing SPMS Abili-T trial

  9. Slide 9: Abili-T: Landmark trial in SPMS

    9 Abili-T: Landmark trial in SPMS • Abili-T Phase IIb clinical trial in SPMS is ongoing – Double-blind, 1:1 randomized, placebo-controlled – Inclusion criteria: Secondary Progressive MS with EDSS of 3 to 6 – 68 patients randomized as of August 8, 2013 – Immune Monitoring program conducted on a blind

  10. Slide 10: Goals and Milestones

    ‘ee OPEXA Goals and Milestones + Present Immune Monitoring base line data at ACTRIMS Conference (2013) + Activate Canadian sites and initiate enrollment in Canada (2013) + Activate and Initiate all Abili-T clinical sites in U.S. (2013) + Advance and complete enrollment in Phase IIb ABILI-T study in

  11. Slide 11: Investment Highlights

    11 Investment Highlights • Lead product, Tcelna®, a T-cell immunotherapy for Multiple Sclerosis (MS) • Currently conducting a Phase 2b clinical trial in Secondary Progressive MS (SPMS) • Limited treatment options currently available for SPMS • Potential SPMS market in North America alone could excee

Opexa Therapeutics — Q2 2013 Earnings Presentation on 6ix